A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Phase 2/3
1,280
about 11 years
18+
42 sites in AL, CA, CO +19
What this study is about
Researchers are testing different treatments for newly diagnosed or recurring glioblastoma. The trial will evaluate several therapies, including drugs, radiation, and other approaches, across a large group of patients.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive ADI-PEG 20
- 2.Receive Radiation
- 3.Take AZD1390
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
lomustine, pi3k inhibitor, regorafenib, temozolomide
oral, oral (Oral Tablet), injection, intravenous
Primary: Overall Survival (OS)
Secondary: Duration of Response (CR + PR), Progression-free survival (PFS), Tumor Response
radiation
Oncology